Background Androgen receptor (AR) pathway inhibition remains the cornerstone for prostate
cancer therapies. However, castration‐resistant prostate cancer (CRPC) tumors can resist …

Most of the updates in the 2015 NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines) for Prostate Cancer center on the systemic therapy front, with a host of newer …

Study Type–Therapy (cohort) Level of Evidence 2a What's known on the subject? and What
does the study add? Despite expanding treatment options for castration‐resistant prostate …

Docetaxel has until recently been the only agent with a small survival benefit for metastatic
castration-resistant prostate cancer (CRPC). To improve clinical outcome in CRPC …

Background Both enzalutamide and abiraterone have demonstrated improved radiographic
progression-free and overall survival for castration-resistant prostate cancer (CRPC) …

Continued research in the treatment of castration-resistant prostate cancer (CRPC) has
allowed for a clearer understanding of this disease entity and further treatment advances. In …

Background Non-metastatic castration resistant prostate cancer (M0CRPC) is a
heterogenous disease state affecting an estimated 100,000 men in the United States …

Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (CRPC), a disease state now recognized to retain …

Abstract Purpose: Abiraterone acetate (AA), an inhibitor of cytochrome P450 17alpha-
hydroxylase/17, 20 lyase, is an FDA-approved drug for advanced prostate cancer. However …

Purpose: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that has
improved overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC) …